As of 2026-10-04, the EV/EBITDA ratio of Sangamo Therapeutics Inc (SGMO) is -0.02. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SGMO's latest enterprise value is 1.88 mil USD. SGMO's TTM EBITDA according to its financial statements is -108.42 mil USD. Dividing these 2 quantities gives us the above SGMO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.8x - 16.9x | 16.2x |
| Forward P/E multiples | 18.8x - 22.1x | 20.4x |
| Fair Price | (12.12) - (10.85) | (11.77) |
| Upside | -6922.6% - -6208.9% | -6729.4% |
| Date | EV/EBITDA |
| 2026-09-22 | 0.03 |
| 2026-09-21 | 0.04 |
| 2026-09-18 | 0.03 |
| 2026-09-17 | 0.04 |
| 2026-09-16 | 0.03 |
| 2026-09-15 | 0.03 |
| 2026-09-14 | 0.03 |
| 2026-09-11 | 0.03 |
| 2026-09-10 | 0.02 |
| 2026-09-09 | 0.02 |
| 2026-09-08 | 0.01 |
| 2026-09-04 | 0.01 |
| 2026-09-03 | 0.00 |
| 2026-09-02 | -0.01 |
| 2026-09-01 | 0.00 |
| 2026-08-31 | 0.00 |
| 2026-08-28 | 0.01 |
| 2026-08-27 | 0.02 |
| 2026-08-26 | 0.02 |
| 2026-08-25 | 0.03 |
| 2026-08-24 | 0.01 |
| 2026-08-21 | 0.04 |
| 2026-08-20 | 0.01 |
| 2026-08-19 | 0.01 |
| 2026-08-18 | 0.01 |
| 2026-08-17 | -0.00 |
| 2026-08-14 | -0.01 |
| 2026-08-13 | 0.00 |
| 2026-08-12 | 0.02 |
| 2026-08-11 | 0.03 |
| 2026-08-10 | 0.07 |
| 2026-08-07 | 0.08 |
| 2026-08-06 | 0.08 |
| 2026-08-05 | 0.10 |
| 2026-08-04 | 0.12 |
| 2026-08-03 | 0.12 |
| 2026-07-31 | 0.14 |
| 2026-07-30 | 0.15 |
| 2026-07-29 | 0.15 |
| 2026-07-28 | 0.15 |
| 2026-07-27 | 0.16 |
| 2026-07-24 | 0.15 |
| 2026-07-23 | 0.14 |
| 2026-07-22 | 0.15 |
| 2026-07-21 | 0.15 |
| 2026-07-20 | 0.14 |
| 2026-07-17 | 0.15 |
| 2026-07-16 | 0.15 |
| 2026-07-15 | 0.15 |
| 2026-07-14 | 0.14 |